Yiling Lu
About
Yiling Lu is a scholar working on Molecular Biology, Oncology and Cancer Research.
According to data from OpenAlex, Yiling Lu has authored 209 papers receiving a total of 15.6k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Molecular Biology, 39 papers in Oncology and 32 papers in Cancer Research. Recurrent topics in Yiling Lu's work include PI3K/AKT/mTOR signaling in cancer (40 papers), Advanced Biosensing Techniques and Applications (25 papers) and Advanced Proteomics Techniques and Applications (19 papers). Yiling Lu is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (40 papers), Advanced Biosensing Techniques and Applications (25 papers) and Advanced Proteomics Techniques and Applications (19 papers). Yiling Lu collaborates with scholars based in United States, China and United Kingdom. Yiling Lu's co-authors include Gordon B. Mills, Bryan T. Hennessy, Prahlad T. Ram, Debra L. Smith, Xianjun Fang, Robert C. Bast, Shuangxing Yu, James R. Woodgett, Ruth LaPushin and Joe W. Gray and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.
In The Last Decade
Yiling Lu
203 papers receiving 15.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yiling Lu United States | 64 | 11.6k | 3.5k | 2.9k | 1.8k | 1.4k | 209 | 15.6k | ||
| Ji Luo United States | 43 | 12.1k 1.0× | 4.2k 1.2× | 2.7k 0.9× | 1.7k 0.9× | 1.5k 1.1× | 99 | 16.0k | ||
| Morag Park Canada | 62 | 8.6k 0.7× | 4.0k 1.1× | 2.4k 0.8× | 1.6k 0.9× | 1.8k 1.3× | 202 | 13.4k | ||
| Linda Z. Penn Canada | 61 | 10.3k 0.9× | 4.0k 1.1× | 4.7k 1.6× | 1.2k 0.7× | 1.3k 0.9× | 139 | 14.7k | ||
| Roderick L. Beijersbergen Netherlands | 48 | 10.9k 0.9× | 5.1k 1.5× | 2.2k 0.8× | 989 0.5× | 1.5k 1.1× | 117 | 15.7k | ||
| David Stokoe United States | 53 | 11.5k 1.0× | 3.5k 1.0× | 2.5k 0.8× | 1.6k 0.9× | 2.1k 1.5× | 96 | 15.7k | ||
| Nicholas Mitsiades United States | 66 | 10.1k 0.9× | 4.5k 1.3× | 2.4k 0.8× | 824 0.5× | 1.9k 1.4× | 172 | 15.3k | ||
| Ju‐Seog Lee United States | 61 | 7.9k 0.7× | 3.7k 1.1× | 3.9k 1.3× | 1.6k 0.9× | 1.2k 0.9× | 218 | 13.3k | ||
| Alfonso Bellacosa United States | 52 | 10.8k 0.9× | 4.0k 1.2× | 2.3k 0.8× | 1.1k 0.6× | 1.3k 1.0× | 118 | 14.4k | ||
| David D.L. Bowtell Australia | 71 | 11.6k 1.0× | 5.4k 1.6× | 3.5k 1.2× | 1.9k 1.0× | 2.2k 1.6× | 221 | 18.4k | ||
| Scott A. Armstrong United States | 69 | 17.0k 1.5× | 3.2k 0.9× | 2.4k 0.8× | 1.2k 0.7× | 2.1k 1.5× | 234 | 22.8k |
Countries citing papers authored by Yiling Lu
Since
Specialization
Citations
This map shows the geographic impact of Yiling Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiling Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiling Lu more than expected).
Fields of papers citing papers by Yiling Lu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yiling Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiling Lu. The network helps show where Yiling Lu may publish in the future.
Co-authorship network of co-authors of Yiling Lu
This figure shows the co-authorship network connecting the top 25 collaborators of Yiling Lu. A scholar is included among the top collaborators of Yiling Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiling Lu. Yiling Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lipchick, Brittany C., Hsin-Yi Chen, Xiangfan Yin, et al.. (2025). Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor–resistant NRAS -mutant melanoma. Science Translational Medicine. 17(784). eadp8913–eadp8913.
2.
Tao, Fangfang, et al.. (2025). The Role of HK2 in Tumorigenesis and Development: Potential for Targeted Therapy with Natural Products. International Journal of Medical Sciences. 22(4). 790–805.
3.
Liu, Wei, Jun Li, Yining Zhao, et al.. (2025). DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis. Nature Communications. 16(1). 2256–2256.
4.
Parashar, Deepak, Anjali Geethadevi, Jasmine George, et al.. (2020). Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Research. 80(24). 5554–5568.
5.
Li, Jun, Rehan Akbani, Wei Zhao, et al.. (2017). Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Research. 77(21). e51–e54.
6.
Zhang, Dongmei, Gao Zhang, Zhongyi Hu, et al.. (2017). Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Research. 77(14). 3745–3757.
7.
Wang, Chao, Chao Gu, Kang Jin Jeong, et al.. (2017). YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor–Induced Activation of the PI3K Pathway. Cancer Research. 77(7). 1637–1648.
8.
Budina-Kolomets, Anna, Marie R. Webster, Julia I-Ju Leu, et al.. (2016). HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research. 76(9). 2720–2730.
9.
Yang, Jiyeon, Henrica M.J. Werner, Jie Li, et al.. (2015). Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clinical Cancer Research. 22(2). 513–523.
10.
Miller, Philip C., Dorraya El‐Ashry, Jun Sun, et al.. (2015). MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clinical Cancer Research. 22(4). 935–947.
11.
Sewell, Andrew, Brandee Brown, Asel Biktasova, et al.. (2014). Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer. Clinical Cancer Research. 20(9). 2300–2311.
12.
Simpkins, Fiona, Jun Sun, Candace A. Gilbert, et al.. (2012). Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo. Clinical Cancer Research. 18(21). 5911–5923.
13.
Cheong, Jae‐Ho, Eun Sung Park, Jiyong Liang, et al.. (2011). Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models. Molecular Cancer Therapeutics. 10(12). 2350–2362.
14.
Cheung, Lydia W.T., Bryan T. Hennessy, Jie Li, et al.. (2011). High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discovery. 1(2). 170–185.
15.
Iadevaia, Sergio, Yiling Lu, Fabiana C. Morales, Gordon B. Mills, & Prahlad T. Ram. (2010). Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis. Cancer Research. 70(17). 6704–6714.
16.
Carey, Mark, Roshan Agarwal, C. Blake Gilks, et al.. (2010). Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy. Clinical Cancer Research. 16(10). 2852–2860.
17.
Park, Eun Sung, Rosalia Rabinovsky, Mark Carey, et al.. (2010). Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set. Molecular Cancer Therapeutics. 9(2). 257–267.
18.
Garlich, Joseph R., Pradip De, Nandini Dey, et al.. (2008). A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. Cancer Research. 68(1). 206–215.
19.
Hennessy, Bryan T., Yiling Lu, Enrique Poradosu, et al.. (2007). Pharmacodynamic Markers of Perifosine Efficacy. Clinical Cancer Research. 13(24). 7421–7431.
20.
Le, Xiao‐Feng, David Gold, Yiling Lu, et al.. (2004). Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. Journal of Biological Chemistry. 280(3). 2092–2104.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ji Luo Breakdown of academic impact, for papers by Morag Park Breakdown of academic impact, for papers by Linda Z. Penn Breakdown of academic impact, for papers by Roderick L. Beijersbergen Breakdown of academic impact, for papers by David Stokoe Breakdown of academic impact, for papers by Nicholas Mitsiades Breakdown of academic impact, for papers by Ju‐Seog Lee Breakdown of academic impact, for papers by Alfonso Bellacosa Breakdown of academic impact, for papers by David D.L. Bowtell Breakdown of academic impact, for papers by Scott A. Armstrong